Efficacy and Safety of Brexpiprazole in Patients with Agitation Associated with Dementia Due to Alzheimer's Disease Analyzed by Presence or Absence of Baseline Psychosis: A Pooled Analysis
Saloni Behl,Alpesh Shah,Denise Chang,Dalei Chen,Zhen Zhang,Daniel Lee,Nanco Hefting,Mary Slomkowski,Uwa Kalu,Alvin Estilo,Anja Farovik,Mary Hobart
DOI: https://doi.org/10.1016/j.jagp.2024.01.175
IF: 7.996
2024-02-22
American Journal of Geriatric Psychiatry
Abstract:Introduction Agitation is a prevalent manifestation of Alzheimer's dementia, which can co-present with psychosis symptoms. Presence of either symptom is associated with accelerated disease progression. This analysis explored the efficacy and safety of brexpiprazole in patients with agitation associated with dementia due to Alzheimer's disease, based on presence or absence of baseline psychosis. Methods This is a post hoc analysis of Phase 3, placebo-controlled trials of brexpiprazole in patients with agitation associated with Alzheimer's dementia (NCT01862640 [fixed-dose], NCT01922258 [flexible-dose], NCT03548584 [fixed-dose]). In each study, the primary endpoint was the change in Cohen-Mansfield Agitation Inventory (CMAI) Total score from baseline to Week 12. Presence of baseline psychosis was defined as a Neuropsychiatric Inventory delusion item and/or hallucination item score ≥4. Efficacy data were pooled from the two fixed-dose studies (brexpiprazole 2 or 3 mg/day compared with placebo). Safety data were pooled from all three studies (brexpiprazole 0.5 - 3 mg/day compared with placebo). Results In the fixed-dose studies (pooled), mean CMAI Total scores at baseline were 82.4 (brexpiprazole 2 or 3 mg/day) and 84.1 (placebo) in patients with baseline psychosis (n=142), and 75.1 and 73.0, respectively, in patients without baseline psychosis (n=465). The mean change in CMAI Total score at Week 12 was -25.1 (brexpiprazole 2 or 3 mg/day) versus -19.1 (placebo) in the subgroup with baseline psychosis (p=0.043), and -20.5 versus -16.3, respectively, in the subgroup without baseline psychosis (p=0.0021). Safety was analyzed using data from 238 patients with baseline psychosis (brexpiprazole 0.5 - 3 mg/day, n=153; placebo, n=85) and 802 patients without baseline psychosis (brexpiprazole 0.5 - 3 mg/day, n=500; placebo, n=302). The incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, and severe TEAEs was generally similar between treatments in each subgroup. The incidence of deaths in patients with baseline psychosis was 1.3% (brexpiprazole 0.5 - 3 mg/day) and 0.0% (placebo), and in patients without baseline psychosis was 0.8% (brexpiprazole 0.5 - 3 mg/day) and 0.3% (placebo). The causes of death were varied, and reflective of the types of events that would be expected in the underlying population. All deaths were considered to be unrelated to study treatment. In patients who received brexpiprazole 0.5 - 3 mg/day and in patients who received placebo, the incidence of falls, sedation, somnolence, TEAEs for cardiovascular events, and TEAEs for cerebrovascular events was <5% in subgroups with and without baseline psychosis. Conclusions In patients with agitation associated with Alzheimer's dementia, with or without baseline psychosis, brexpiprazole was associated with improvement in symptoms of agitation compared with placebo and had a similar safety profile.
psychiatry,geriatrics & gerontology,gerontology